Functional POR A503V is associated with the risk of bladder cancer in a Chinese population

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Xiao, Xue ^a,b   Ma, Gaoxiang ^a   Li, Shushu ^a,b   Wang, Meilin ^a   Liu, Nian ^a,b   Ma, Lan ^a   Zhang, Zhan ^a,b   Chu, Haiyan ^a   Zhang, Zhengdong ^a   Wang, Shou Lin ^a,b  

^a Nanjing Medical University   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; POR PROTEIN, HUMAN;

AGED; ANIMAL; BLADDER TUMOR; CASE CONTROL STUDY; CHINA; CHO CELL LINE; CRICETULUS; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; HAMSTER; HUMAN; MALE; MIDDLE AGED; MISSENSE MUTATION; PROTECTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANIMALS; CASE-CONTROL STUDIES; CHINA; CHO CELLS; CRICETINAE; CRICETULUS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTECTIVE FACTORS; RISK FACTORS; SEQUENCE ANALYSIS, DNA; URINARY BLADDER NEOPLASMS;

EID: 84934777303     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11751     Document Type: Article

References (53)

1. Institute, N. C. SEER Cancer Statistics Review, 1975-2006, (2009). Available at: http://seer.cancer.gov/csr/1975-2006/. (Accessed: 15/04/2009).
2. Zeegers, M. P., Kellen, E., Buntinx, F. & van den Brandt, P. A. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World. J. Urol. 21, 392-401, doi: 10.1007/s00345-003-0382-8 (2004).
3. Shariat, S. F., Milowsky, M. & Droller, M. J. Bladder cancer in the elderly. Urol. Oncol. 27, 653-667, doi: 10.1016/j. urolonc.2009.07.020 (2009).
4. Rothman, N. et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet. 42, 978-984, doi: 10.1038/ng.687 (2010).
5. Kiemeney, L. A. et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat. Genet. 40, 1307-1312, doi: 10.1038/ng.229 (2008).
6. Wu, X. et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat. Genet. 41, 991-995, doi: 10.1038/ng.421 (2009)
7. Rafnar, T. et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41, 221-227, doi: 10.1038/ng.296 (2009).
8. Kiemeney, L. A. et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat. Genet. 42, 415-419, doi: 10.1038/ng.558 (2010).
9. Garcia-Closas, M. et al. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum. Mol. Genet. 20, 4282-4289, doi: 10.1093/hmg/ddr342 (2011).
10. Rafnar, T. et al. European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum. Mol. Genet. 20, 4268-4281, doi: 10.1093/hmg/ddr303 (2011).
11. Figueroa, J. D. et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum. Mol. Genet. 23, 1387-1398, doi: 10.1093/hmg/ddt519 (2014).
12. Ma, L. et al. hOGG1 Ser326Cys polymorphism is associated with risk of bladder cancer in a Chinese population: a case-control study. Cancer. Sci. 103, 1215-1220, doi: 10.1111/j.1349-7006.2012.02290.x (2012).
13. Yuan, J. M. et al. Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. Carcinogenesis. 29, 1386-1393, doi: 10.1093/carcin/bgn136 (2008).
14. Choi, J. Y. et al. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics. 13, 349-355, doi: 10.1097/01. fpc.0000054096.48725.25 (2003).
15. Wu, K. et al. Glutathione S-transferase P1 gene polymorphism and bladder cancer susceptibility: an updated analysis. Mol. Biol. Rep. 40, 687-695, doi: 10.1007/s11033-012-2109-7 (2013).
16. Garcia-Closas, M. et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 366, 649-659, doi: 10.1016/S0140-6736(05)67137-1 (2005).
17. Hein, D. W. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene. 25, 1649-1658, doi: 10.1038/sj.onc.1209374 (2006).
18. Garcia-Closas, M. et al. Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer. Res. 73, 2211-2220, doi: 10.1158/0008-5472.CAN-12-2388 (2013).
19. Horecker, B. L. & Heppel, L. A. The reduction of cytochrome c by xanthine oxidase. J. Biol. Chem. 178, 683-690 (1949).
20. Miller, W. L. Minireview: regulation of steroidogenesis by electron transfer. Endocrinology. 146, 2544-2550, doi: 10.1210/en.2005-0096 (2005).
21. Nishino, H. & Ishibashi, T. Evidence for requirement of NADPH-cytochrome P450 oxidoreductase in the microsomal NADPHsterol Delta7-reductase system. Arch. Biochem. Biophys. 374, 293-298, doi: 10.1006/abbi.1999.1602 (2000).
22. Han, J. F. et al. Effect of genetic variation on human cytochrome p450 reductase-mediated paraquat cytotoxicity. Toxicol. Sci. 91, 42-48, doi: 10.1093/toxsci/kfj139 (2006).
23. Wang, S. L. et al. Genetic variation of human cytochrome p450 reductase as a potential biomarker for mitomycin C-induced cytotoxicity. Drug. Metab. Dispos. 35, 176-179, doi: 10.1124/dmd.106.011056 (2007).
24. Otto, D. M. et al. Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic Acid homeostasis. Mol. Cell. Biol. 23, 6103-6116 (2003).
25. Gu, J. et al. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J. Biol. Chem. 278, 25895-25901, doi: 10.1074/jbc.M303125200 (2003).
26. Scott, R. R. et al. Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 92, 2318-2322, doi: 10.1210/jc.2006-2345 (2007).
27. Fluck, C. E. et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat. Genet. 36, 228-230, doi: 10.1038/ng1300 (2004).
28. Huang, N. et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet. 76, 729-749, doi: 10.1086/429417 (2005).
29. Miller, W. L. et al. Consequences of POR mutations and polymorphisms. Mol. Cell. Endocrinol. 336, 174-179, doi: 10.1016/j. mce.2010.10.022 (2011).
30. Hart, S. N. et al. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet. Genomics. 18, 11-24, doi: 10.1097/FPC.0b013e3282f2f121 (2008).
31. Arlt, W. et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet. 363, 2128-2135, doi: 10.1016/S0140-6736(04)16503-3 (2004).
32. Haiman, C. A. et al. A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans. Cancer. Res. 67, 3565-3568, doi: 10.1158/0008-5472.CAN-06-4801 (2007).
33. Huang, N., Agrawal, V., Giacomini, K. M. & Miller, W. L. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc. Natl. Acad Sci USA 105, 1733-1738, doi: 10.1073/pnas.0711621105 (2008).
34. Yang, G. et al. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. Clin. Ther. 33, 2060-2070, doi: 10.1016/j.clinthera.2011.11.004 (2011).
35. Zeegers, M. P., Tan, F. E., Dorant, E. & van Den Brandt, P. A. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 89, 630-639 (2000).
36. Conney, A. H. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. Cancer. Res. 42, 4875-4917 (1982).
37. Kim, D. & Guengerich, F. P. Cytochrome P450 activation of arylamines and heterocyclic amines. Annu. Rev. Pharmacol. Toxicol. 45, 27-49, doi: 10.1146/annurev.pharmtox.45.120403.100010 (2005).
38. Gunes, A. et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics. 10, 769-778, doi: 10.2217/pgs.09.22 (2009).
39. Sim, S. C. & Ingelman-Sundberg, M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum. Genomics. 4, 278-281 (2010).
40. Agrawal, V., Huang, N. & Miller, W. L. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet. Genomics. 18, 569-576, doi: 10.1097/FPC.0b013e32830054ac (2008).
41. Dobrinas, M., Cornuz, J., Pedrido, L. & Eap, C. B. Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking. Pharmacogenet. Genomics. 22, 143-151, doi: 10.1097/FPC.0b013e32834e9e1a (2012).
42. Agrawal, V., Choi, J. H., Giacomini, K. M. & Miller, W. L. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet. Genomics. 20, 611-618, doi: 10.1097/FPC.0b013e32833e0cb5 (2010).
43. Patten, C. J. et al. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes. Carcinogenesis. 18, 1623-1630 (1997).
44. Garcia-Perez, J. et al. Mortality due to lung, laryngeal and bladder cancer in towns lying in the vicinity of combustion installations. Sci. Total. Environ. 407, 2593-2602, doi: 10.1016/j.scitotenv.2008.12.062 (2009).
45. Chen, H. I. et al. Bladder cancer screening and monitoring of 4,4'-methylenebis(2-chloroaniline) exposure among workers in Taiwan. Urology. 66, 305-310, doi: 10.1016/j.urology.2005.02.031 (2005).
46. Snyderwine, E. G., Sinha, R., Felton, J. S. & Ferguson, L. R. Highlights of the eighth international conference on carcinogenic/ mutagenic N-substituted aryl compounds. Mutat. Res. 506-507, 1-8 (2002).
47. Leppert, J. T. et al. Prevention of bladder cancer: a review. Eur. Urol. 49, 226-234, doi: 10.1016/j.eururo.2005.12.011 (2006).
48. Miyamoto, H. et al. Promotion of bladder cancer development and progression by androgen receptor signals. J. Natl. Cancer. Inst. 99, 558-568, doi: 10.1093/jnci/djk113 (2007).
49. Boorjian, S. A. et al. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr. Relat. Cancer. 16, 123-137, doi: 10.1677/ERC-08-0124 (2009).
50. Wu, J. T. et al. Androgen receptor is a potential therapeutic target for bladder cancer. Urology. 75, 820-827, doi: 10.1016/j. urology.2009.10.041 (2010).
51. Miller, W. L. Steroidogenic enzymes. Endocr. Dev. 13, 1-18, doi: 10.1159/000134751 (2008).
52. Miller, W. L., Huang, N., Agrawal, V. & Giacomini, K. M. Genetic variation in human P450 oxidoreductase. Mol. Cell. Endocrinol. 300, 180-184, doi: 10.1016/j.mce.2008.09.017 (2009).
53. Paroni, R. et al. Plasma mitomycin C concentrations determined by HPLC coupled to solid-phase extraction. Clin. Chem. 43, 615-618 (1997).